bioAffinity Technologies, Inc. (BIAF)
9.93
-0.57
(-5.43%)
USD |
NASDAQ |
Sep 10, 13:28
bioAffinity Technologies Profit Margin (Quarterly) : -222.8% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -222.8% |
| March 31, 2026 | -268.6% |
| December 31, 2025 | -197.0% |
| September 30, 2025 | -349.3% |
| June 30, 2025 | -319.9% |
| March 31, 2025 | -143.5% |
| December 31, 2024 | -134.4% |
| September 30, 2024 | -85.13% |
| June 30, 2024 | -88.01% |
| Date | Value |
|---|---|
| March 31, 2024 | -81.52% |
| December 31, 2023 | -107.2% |
| September 30, 2023 | -767.5% |
| June 30, 2023 | -8.83K% |
| March 31, 2023 | -170.3K% |
| December 31, 2022 | -72.81K% |
| September 30, 2022 | -410.0K% |
| June 30, 2022 | -6.78K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 10.15% |
| Perspective Therapeutics, Inc. | -33.31K% |
| MiMedx Group, Inc. | -23.06% |
| Veracyte, Inc. | 16.96% |
| ABVC BioPharma, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -353.6% |
| Return on Assets | -177.3% |
| Return on Invested Capital | -283.3% |
| Gross Profit Margin (Quarterly) | 23.91% |
| Operating Margin (Quarterly) | -220.8% |
| Return on Net Operating Assets | -363.0% |